Stockreport

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF Presentation highlights Nurix’s innovation and leadership in targeted protein modulation, including ligase inhibition Unique mechanism of action, an intramolecular glue [Read more]